{"prompt": "['IRB Approved', '9984', 'Document Release Date: 03/25/2021', 'Clinical Study Protocol', 'Drug Substance Olaparib (AZD2281, KU-0059436); Testosterone', 'Consortium Study Number 9984', 'Edition Number 1.6', 'Date February 24, 2021', '90.', 'Mirza MR, Monk BJ, Herrstedt J et al. Niraparib Maintenance Therapy in Platinum-', 'Sensitive, Recurrent Ovarian Cancer. N Engl J Med 2016; 375: 2154-2164.', '91.', 'Scott CL, Swisher EM, Kaufmann SH. Poly (ADP-ribose) polymerase inhibitors:', 'recent advances and future development. J Clin Oncol 2015; 33: 1397-1406.', '92.', 'Gojo I, Beumer JH, Pratz KW et al. A Phase 1 Study of the PARP Inhibitor Veliparib', 'in Combination with Temozolomide in Acute Myeloid Leukemia. Clin Cancer Res 2016.', '93.', 'de Bono J, Mateo J, Fizazi K et al. Olaparib for Metastatic Castration-Resistant', 'Prostate Cancer. N Engl J Med 2020.', '94.', 'Menear KA, Adcock C, Boulter R et al. 4-[3-(4-cyclopropanecarbonylpiperazine-1-', 'carbonyl)-4-fluorobenzyl]-2H-phthalazin- 1-one: a novel bioavailable inhibitor of poly(ADP-', 'ribose) polymerase-1 J Med Chem 2008; 51: 6581-6591.', '95.', 'Scher HI, Morris MJ, Stadler WM et al. Trial Design and Objectives for Castration-', 'Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical', 'Trials Working Group 3. J Clin Oncol 2016; 34: 1402-1418.', '96.', 'Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid', 'tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247.', '97.', 'Pritchard CC, Salipante SJ, Koehler K et al. Validation and implementation of targeted', 'capture and sequencing for the detection of actionable mutation, copy number variation, and', 'gene rearrangement in clinical cancer specimens. The Journal of molecular diagnostics : JMD', '2014; 16: 56-67.', '98.', 'Campton DE, Ramirez AB, Nordberg JJ et al. High-recovery visual identification and', 'single-cell retrieval of circulating tumor cells for genomic analysis using a dual-technology', 'platform integrated with automated immunofluorescence staining. BMC Cancer 2015; 15:', '360.', '99.', 'Kalhorn TF, Page ST, Howald WN et al. Analysis of testosterone and', 'dihydrotestosterone from biological fluids as the oxime derivatives using high-performance', 'liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2007; 21:', '3200-3206.', '100. Cho E, Mostaghel EA, Russell KJ et al. External beam radiation therapy and', 'abiraterone in men with localized prostate cancer: safety and effect on tissue androgens. Int J', 'Radiat Oncol Biol Phys 2015; 92: 236-243.', '101. Taplin ME, Montgomery B, Logothetis CJ et al. Intense androgen-deprivation therapy', 'with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate', 'cancer: results of a randomized phase II neoadjuvant study. J Clin Oncol 2014; 32: 3705-', '3715.', '102. Mostaghel EA, Nelson PS, Lange P et al. Targeted androgen pathway suppression in', 'localized prostate cancer: a pilot study. J Clin Oncol 2014; 32: 229-237.', '103. Esper P, Mo F, Chodak G et al. Measuring quality of life in men with prostate cancer', 'using the functional assessment of cancer therapy-prostate instrument. Urology 1997; 50: 920-', '928.', '104.', 'Hays RD, Sherbourne CD, Mazel RM. The RAND 36-Item Health Survey 1.0. Health', 'Econ 1993; 2: 217-227.', '105. Logothetis CJ, Lin SH. Osteoblasts in prostate cancer metastasis to bone. Nat Rev', 'Cancer 2005; 5: 21-28.', '83(93)', 'Printed on 3/25/202']['IRB Approved', '9984', 'Document Release Date: 03/25/2021', 'Clinical Study Protocol', 'Drug Substance Olaparib (AZD2281, KU-0059436); Testosterone', 'Consortium Study Number 9984', 'Edition Number 1.6', 'Date February 24, 2021', '84(93)', 'Printed on 3/25/202']\n\n###\n\n", "completion": "END"}